The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...

Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution, the ...

Imkeldi is supplied as a strawberry-flavored oral solution in a 140 mL, child-resistant, tamper-evident bottle. The US Food and Drug Administration (FDA) has approved Imkeldi, an oral solution ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “ammunition in the war against cancer.” Along with a picture of the ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

In the setting of clinical trials, high-dose imatinib, imatinib dose optimization according to response (Therapeutic Intensification in De novo Leukemia [TIDEL] studies, Australian approach), the ...